Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation
- Conditions
- Single Ventricle Physiology
- Registration Number
- NCT02995577
- Brief Summary
The purpose of this study is to investigates serum and stool biomarkers as predictors for post-operative feeding intolerance in infant patients with complex congenital heart defects who undergo single ventricle staged palliation surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Full term gestational period (37 weeks gestation or greater)
- minimum of 2.5kg or greater body weight
- diagnosis of single ventricle physiology, or complex congenital cyanotic heart disease requiring staged palliation surgery in the form of Norwood-type procedure, systemic-to-pulmonary artery shunt, or pulmonary artery banding.
Exclusion Criteria
- Have diseases affecting other organs,
- have major congenital anomalies such as Hirschsprung disease, imperforate anus, CHARGE syndrome, or VACTERL association.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Level of second most abundant serum protein as determined by ELISA baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery Level of stool biomarker interleukin-8 (IL-8) as determined by ELISA baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery Level of most abundant serum protein as determined by ELISA baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery We will select two proteins with top changes that are involved in the pathways for intestinal inflammation, and levels will be determined with either ELISA or other techniques that are available.
Level of stool biomarker calprotectin as determined by ELISA baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The University of Texas Health Science Center at Houston
πΊπΈHouston, Texas, United States
The University of Texas Health Science Center at HoustonπΊπΈHouston, Texas, United StatesSupriya Nair, MDContact832-582-0683Supriya.Nair@uth.tmc.edu
